A post-hoc analysis of the Prasinezumab trial in early Parkinson's disease
Автор: International Parkinson and Movement Disorder Society
Загружено: 2024-07-15
Просмотров: 304
Dr. Gennaro Pagano discusses the findings of the post-hoc analysis of the PASADENA trial, a study using the monoclonal antibody Prasinezumab directed at aggregated α-synuclein, where motor progression trajectories differed between active and placebo groups. Read article » (https://pubmed.ncbi.nlm.nih.gov/38622...)
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке: